RedHill Biopharma (RDHL) Notes Payables (2022)

RedHill Biopharma's (RDHL) quarterly Notes Payables came in at $115.2 million in Q4 2022.

RedHill Biopharma (RDHL) Notes Payables (2022) Analysis & Trends

RedHill Biopharma (RDHL) has 1 years of Notes Payables data on file, last reported at $115.2 million in Q4 2022.

  • On a quarterly basis, Notes Payables changed N/A year-over-year to $115.2 million in Q4 2022; TTM through Dec 2022 was $115.2 million, a N/A change from a year earlier, with the FY2022 full-year figure at $115.2 million, changed N/A from the prior year.
  • Notes Payables for Q4 2022 stood at $115.2 million.
  • Over the last five years, Notes Payables for RDHL reached as high as $115.2 million in Q4 2022 and fell as low as $115.2 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 RedHill Biopharma 640,064.98 640,064.98 -

Historic Data

Download Data
DateValue
Dec 31, 2022 115.22 Mn